Lurasidone in schizophrenia: new information about dosage and place in therapy.
Citrome L.
Adv Ther · review; journal article · DOI 10.1007/s12325-012-0052-6 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för lurasidone. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
24 träffarBody weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.
De Hert M, Yu W, Detraux J, Sweers K, van Winkel R, Correll CU.
CNS Drugs · meta-analysis; research support, non-u.s. gov't; systematic review; journal article · DOI 10.2165/11634500-000000000-00000Structural insight into receptor-selectivity for lurasidone.
Ichikawa O, Okazaki K, Nakahira H, Maruyama M, Nagata R, Tokuda K, Horisawa T, Yamazaki K.
Neurochem Int · journal article · DOI 10.1016/j.neuint.2012.08.005Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study.
Ogasa M, Kimura T, Nakamura M, Guarino J.
Psychopharmacology (Berl) · research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1007/s00213-012-2838-2Evaluation of dopamine D₂/D₃ and serotonin 5-HT₂A receptor occupancy for a novel antipsychotic, lurasidone, in conscious common marmosets using small-animal positron emission tomography.
Nakazawa S, Yokoyama C, Nishimura N, Horisawa T, Kawasaki A, Mizuma H, Doi H, Onoe H.
Psychopharmacology (Berl) · comparative study; research support, non-u.s. gov't; journal article · DOI 10.1007/s00213-012-2815-9Iloperidone, asenapine and lurasidone: a primer on their current status.
Tarazi FI, Stahl SM.
Expert Opin Pharmacother · comparative study; review; journal article · DOI 10.1517/14656566.2012.712114Lurasidone: an atypical antipsychotic for schizophrenia.
Risbood V, Lee JR, Roche-Desilets J, Fuller MA.
Ann Pharmacother · review; journal article · DOI 10.1345/aph.1m721Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?
Citrome L.
Clin Schizophr Relat Psychoses · clinical trial, phase iii; clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal articlePrevention of the phencyclidine-induced impairment in novel object recognition in female rats by co-administration of lurasidone or tandospirone, a 5-HT(1A) partial agonist.
Horiguchi M, Hannaway KE, Adelekun AE, Jayathilake K, Meltzer HY.
Neuropsychopharmacology · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/npp.2012.64Update on the development of lurasidone as a treatment for patients with acute schizophrenia.
Yasui-Furukori N.
Drug Des Devel Ther · review-article; review; journal article · DOI 10.2147/dddt.s11180A review of published evidence reporting on the efficacy and pharmacology of lurasidone.
McIntyre RS, Cha DS, Alsuwaidan M, McIntosh D, Powell AM, Jerrell JM.
Expert Opin Pharmacother · review; journal article · DOI 10.1517/14656566.2012.683174Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study.
Citrome L, Cucchiaro J, Sarma K, Phillips D, Silva R, Tsuchiya S, Loebel A.
Int Clin Psychopharmacol · research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1097/yic.0b013e32835281ef5-HT1A and 5-HT7 receptors contribute to lurasidone-induced dopamine efflux.
Huang M, Horiguchi M, Felix AR, Meltzer HY.
Neuroreport · research support, non-u.s. gov't; journal article · DOI 10.1097/wnr.0b013e328352de40Lurasidone (latuda®): an atypical antipsychotic.
Nolan SF, Roman MW.
Issues Ment Health Nurs · review; journal article · DOI 10.3109/01612840.2012.669025Critical appraisal of lurasidone in the management of schizophrenia.
Caccia S, Pasina L, Nobili A.
Neuropsychiatr Dis Treat · review-article; journal article · DOI 10.2147/ndt.s18059Lurasidone for schizophrenia: what's different?
Kantrowitz JT, Citrome L.
Expert Rev Neurother · research support, non-u.s. gov't; review; journal article; research support, n.i.h., extramural · DOI 10.1586/ern.12.7Interactions between antiepileptics and second-generation antipsychotics.
de Leon J, Santoro V, D'Arrigo C, Spina E.
Expert Opin Drug Metab Toxicol · review; journal article · DOI 10.1517/17425255.2012.660918The role of 5-HT1A receptors in phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats.
Horiguchi M, Meltzer HY.
Psychopharmacology (Berl) · comparative study; research support, non-u.s. gov't; journal article · DOI 10.1007/s00213-011-2561-4The novel antipsychotic drug lurasidone enhances N-methyl-D-aspartate receptor-mediated synaptic responses.
Yuen EY, Li X, Wei J, Horiguchi M, Meltzer HY, Yan Z.
Mol Pharmacol · research-article; journal article; research support, n.i.h., extramural · DOI 10.1124/mol.111.076141Pharmacokinetics of lurasidone, a novel atypical anti-psychotic drug, in rats.
Lee KR, Chae YJ, Koo TS.
Xenobiotica · journal article · DOI 10.3109/00498254.2011.603388Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics.
Citrome L.
Postgrad Med · review; journal article · DOI 10.3810/pgm.2011.03.2273Modulation of BDNF expression by repeated treatment with the novel antipsychotic lurasidone under basal condition and in response to acute stress.
Fumagalli F, Calabrese F, Luoni A, Bolis F, Racagni G, Riva MA.
Int J Neuropsychopharmacol · research support, non-u.s. gov't; journal article · DOI 10.1017/s1461145711000150Lurasidone: a clinical overview.
Kane JM.
J Clin Psychiatry · review; journal article · DOI 10.4088/jcp.10075su1.05Lurasidone: a new drug in development for schizophrenia.
Meyer JM, Loebel AD, Schweizer E.
Expert Opin Investig Drugs · research support, non-u.s. gov't; review; journal article; research support, n.i.h., extramural · DOI 10.1517/13543780903286388